Skip to main content

Marcos Lacasa Cazcarra

Institutions of which they are part

Postdoctoral researcher
Rheumatology
Vall Hebron Institut de Recerca

Marcos Lacasa Cazcarra

Institutions of which they are part

Postdoctoral researcher
Rheumatology
Vall Hebron Institut de Recerca

Related news

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.

The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).

Related professionals

Borja Garcia Centrich

Borja Garcia Centrich

Gestió i Administració
Unitat legal
Legal Directorate
Read more
Pilar Bonet Palomares

Pilar Bonet Palomares

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
José Alonso Fajardo

José Alonso Fajardo

Shock, Organ Dysfunction and Resuscitation
Read more
Nuria Nogués Gálvez

Nuria Nogués Gálvez

Senior researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.